Antifungal activity of the naphthoquinone betalapachone against disseminated infection with cryptococcus neoformans var. neoformans in dexamethasone-immunosuppressed Swiss mice

Brazilian Journal of Medical and Biological Research

Volumn 43, Issue 4, 2010, Pages 345-349

  Medeiros, C S ^a   Pontes Filho, N T ^a   Camara, C A ^b   Lima Filho, J V ^b   Oliveira, P C ^a   Lemos, S A ^a   Leal, A F G ^a   Brandao J O C ^a   Neves, R P ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b UNIVERSIDADE FEDERAL RURAL DE PERNAMBUCO   (Brazil)

Author keywords

Amphotericin B; Beta lapachone; Cryptococcosis; Cryptococcus neoformans; Experimental infection; Immunosuppression

Indexed keywords

AMPHOTERICIN B; BETA LAPACHONE; DEXAMETHASONE; NAPHTHOQUINONE; PHOSPHATE BUFFERED SALINE;

ABDOMINAL DISCOMFORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; BRAIN INFECTION; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SCREENING; FUNGAL COLONIZATION; FUNGAL DETECTION; FUNGUS GROWTH; HEPATITIS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IN VIVO STUDY; LEUKOCYTE COUNT; LUNG INFECTION; MALE; MORTALITY; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; SPLEEN DISEASE; SWISS WEBSTER MOUSE; SYSTEMIC MYCOSIS;

ANIMALIA; CRYPTOCOCCUS NEOFORMANS VAR. NEOFORMANS; FILOBASIDIELLA NEOFORMANS; MUS;

EID: 77951898596     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2010007500012     Document Type: Article

References (20)

1. Perfect JR, Casadevall A. Cryptococcosis. Infect Dis Clin North Am 2002; 16: 837-874.
2. Barbosa FM, Fonseca FL, Holandino C, Alviano CS, Nimrichter L, Rodrigues ML. Glucuronoxylomannan-mediated interaction of Cryptococcus neoformans with human alveolar cells results in fungal internalization and host cell damage. Microbes Infect 2006; 8: 493-502.
3. Chen SH, Stins MF, Huang SH, Chen YH, Kwon-Chung KJ, Chang Y, et al. Cryptococcus neoformans induces alterations in the cytoskeleton of human brain microvascular endothelial cells. J Med Microbiol 2003; 52: 961-970.
4. Chakrabarti A. Epidemiology of central nervous system mycoses. Neurol India 2007; 55: 191-197.
5. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337: 15-21.
6. Mondello F, De Bernardis F, Girolamo A, Salvatore G, Cassone A. In vitro and in vivo activity of tea tree oil against azole-susceptible and -resistant human pathogenic yeasts. J Antimicrob Chemother 2003; 51: 1223-1229.
7. Salas C, Tapia RA, Ciudad K, Armstrong V, Orellana M, Kemmerling U, et al. Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms. Bioorg Med Chem 2008; 16: 668-674.
8. Pereira EM, Machado TB, Leal IC, Jesus DM, Damaso CR, Pinto AV, et al. Tabebuia avellanedae naphthoquinones: activity against methicillin-resistant staphylococcal strains, cytotoxic activity and in vivo dermal irritability analysis. Ann Clin Microbiol Antimicrob 2006; 5: 5.
9. Blanco E, Bey EA, Dong Y, Weinberg BD, Sutton DM, Boothman DA, et al. Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1- overexpressing tumor cells. J Control Release 2007; 122: 365-374.
10. Guiraud P, Steiman R, Campos-Takaki GM, Seigle-Murandi F, Simeon de BM. Comparison of antibacterial and antifungal activities of lapachol and beta-lapachone. Planta Med 1994; 60: 373-374.
11. Cavalcante FA, Silva JLV, Carvalho VMN, Camara CA, Silva TM, Pinto AC, et al. Spasmolytic activity of lapachol and its derivatives, alpha and beta-lapachone, on the guinea-pig ileum involves blockade of voltage-gated calcium channels. Rev Bras Farmacog 2008; 18: 183-189.
12. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard M27-A3. CLSI. 3rd edn. Villanova: NCCLS; 2002.
13. Capilla J, Maffei CM, Clemons KV, Sobel RA, Stevens DA. Experimental systemic infection with Cryptococcus neoformans var. grubii and Cryptococcus gattii in normal and immunodeficient mice. Med Mycol 2006; 44: 601-610.
14. Santana CF, Lima OG, D'Albuquerque IL, Lacerda AL, Martins DG. Observações sobre as propriedades antitumorais e toxicológicas do extrato do líber e de alguns componentes do cerne do Pau d'arco (Tabebuia avellanedae). Rev Inst Antib 1968; 8: 89-94.
15. Howland JL. The reversibility of inhibition by 2-heptyl-4-hydroxyquinoline-n-oxide and 2-hydroxy-3(3-methylbutyl)-1,4- naphthoquinone of succinate oxidation. Biochim Biophys Acta 1963; 73: 665-667.
16. Schop J. Protective immunity against Cryptococcus neoformans infection. Mcgill J Med 2007; 10: 35-43.
17. Franchimont D, Galon J, Gadina M, Visconti R, Zhou Y, Aringer M, et al. Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J Immunol 2000; 164: 1768-1774.
18. Moon DO, Choi YH, Kim ND, Park YM, Kim GY. Anti-inflammatory effects of beta-lapachone in lipopolysaccharide-stimulated BV2 microglia. Int Immunopharmacol 2007; 7: 506-514.
19. Hossain MA, Maesaki S, Mitsutake K, Kakeya H, Sasaki E, Tomono K, et al. In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans. J Antimicrob Chemother 1999; 44: 827-829.
20. Kakeya H, Miyazaki Y, Senda H, Kobayashi T, Seki M, Izumikawa K, et al. Efficacy of SPK-843, a novel polyene antifungal, in a murine model of systemic cryptococcosis. Antimicrob Agents Chemother 2008; 52: 1871-1872.